Overcoming the translational gap between preclinical CNS models and human outcomes
10 Sept 2026
Preclinical Models
- What are the main reasons preclinical CNS models often fail to predict human clinical outcomes?
- How can we improve the biological relevance of animal and in vitro CNS models to better reflect human disease mechanisms?
- Which biomarkers or translational endpoints can help bridge findings from preclinical studies to clinical trials?
- How can human-derived models, such as organoids, iPSC-based systems, or ex vivo tissues, strengthen CNS drug development?
- What changes in study design, validation, and reproducibility standards are needed to improve translation from bench to bedside?
